Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?
- 1 May 2004
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 13 (5) , 312-316
- https://doi.org/10.1191/0961203304lu1018oa
Abstract
B cell dysfunctionand pathogenicautoantibodyformationare thoughtto be criticalin the pathogenesis of systemic lupus erythematosus (SLE). In this review we will summarize the results of attempts to utilize B cell depletion, based on the use of a chimeric monoclonalantibody(MAb) specific for human CD20, rituximab, for the treatment of patients with SLE.Keywords
This publication has 30 references indexed in Scilit:
- Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletionAnnals of the Rheumatic Diseases, 2002
- Anti‐CD20 monoclonal antibody (Rituximab) for life‐threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosusBritish Journal of Haematology, 2002
- Interleukin 10: a new therapeutic target in systemic lupus erythematosus?Joint Bone Spine, 2001
- Cytokines and systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2000
- Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)—relation to Th1- and Th2-derived cytokinesClinical and Experimental Immunology, 1999
- Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α Levels and Disease Acitivity in Systemic Lupus ErythematosusClinical Rheumatology, 1999
- 1 Immunopathogenesis of SLEBailliere's Clinical Rheumatology, 1998
- Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activityLupus, 1995
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- RHEUMATOID ARTHRITIS: A DISEASE OF T-LYMPHOCYTE/MACROPHAGE IMMUNOREGULATIONThe Lancet, 1981